@article{chevallier:inserm-02913620, TITLE = {{⁹⁰Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study}}, AUTHOR = {Chevallier, Patrice and Eug{\`e}ne, Thomas and Robillard, Nelly and Isnard, Fran{\c c}oise and Nicolini, Franck and Escoffre Barbe, Martine and Huguet, Fran{\c c}oise and Hunault, Mathilde and Mar{\c c}ais, Antoine and Gaschet, Jo{\"e}lle and Cherel, Michel and Guillaume, Thierry and Delaunay, Jacques and Peterlin, Pierre and Eveillard, Marion and Thomas, Xavier and Ifrah, Norbert and Lapusan, Simona and Bodet-Milin, Caroline and Barbet, Jacques and Faivre-Chauvet, Alain and Ferrer, Ludovic and Bene, Marie and Le Houerou, Claire and Goldenberg, David M and Wegener, William and Kraeber-Bod{\'e}r{\'e}, Fran{\c c}oise}, URL = {https://www.hal.inserm.fr/inserm-02913620}, JOURNAL = {{The Lancet}}, PUBLISHER = {{Elsevier}}, VOLUME = {2}, NUMBER = {3}, PAGES = {e108-17}, YEAR = {2015}, DOI = {10.1016/S2352-3026(15)00020-4}, PDF = {https://www.hal.inserm.fr/inserm-02913620/file/2015_Chevallier%20P_LancetHaematolEq13.pdf}, HAL_ID = {inserm-02913620}, HAL_VERSION = {v1}, }